Cure8 trial brief
The study could improve prediction of who among first-degree relatives will develop Crohn's disease by combining blood biomarkers and lifestyle data, which may help earlier detection or targeted monitoring.
First-degree relatives of people with Crohn's disease; gastroenterologists and IBD clinics; researchers focused on IBD risk, biomarkers, and prevention.
PREDICT-CD will enroll relatives aged 16–35 at 28 centres across seven European countries. At baseline relatives provide serum (mandatory) and may optionally give whole blood and stool; they also complete health and lifestyle questionnaires. Patients with Crohn's disease provide clinical history to link family risk.
Relatives are followed with questionnaires every six months and any Crohn's diagnosis during follow-up is confirmed using endoscopy and biopsy per standard criteria.
This is an observational, recruiting clinical study (planned enrollment 10,000) within the INTERCEPT consortium and follows participants up to three years. As a trial record, the entry presents planned design and outcomes rather than study findings.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
New oral TYK2 inhibitor data show promise on endoscopic healing and inflammatory markers in Crohn’s disease, which is important because oral treatment options are limited. However, the trial missed its main symptom-based...
This project aims to detect Crohn’s before symptoms appear and test preventive treatment—research that could change diagnosis and care for people with family risk. Successful biomarkers could allow earlier monitoring or...
A study aiming to identify who is likely to develop Crohn’s disease and to test preventing it could eventually allow truly early treatment before symptoms begin. If successful, validated biomarkers and a risk score could...
